For in vitro diagnostic use. Others cobas EBV Test 5800-6800-8800 IVD cobas® EBV PID00000152 Quantitative nucleic acid test for use on the cobas® 5800/6800/8800 systems 09 040 943 190 9 040 943 190 09040943190 9040943190 09040943190 KIT COBAS 58/68/8800 EBV 192T IVD KIT COBAS 58/68/8800 EBV 192T IVD 00875197006797 Reagents, kits 1 Kit 192 tests true cobas® EBV is an in vitro nucleic acid amplification test for the quantitation of Epstein-Barr virus (EBV) DNA in human EDTA plasma on the cobas® 5800/6800/8800 Systems.cobas® EBV is intended for use as an aid in the management of EBV in transplant patients. In patients undergoing monitoring of EBV, serial DNA measurements can be used to indicate the need for potential treatment changes and to assess response to treatment.The results from cobas® EBV are intended to be read and analyzed by a qualified licensed healthcare professional in conjunction with clinical signs and symptoms and relevant laboratory findings. Negative test results do not preclude EBV infection or EBV disease. Test results must not be the sole basis for patient management decisions.cobas® EBV is not intended for use as a screening test for donors of blood or blood products or human cells, tissues, and cellular and tissue-based products (HCT/Ps). en cobas® EBV is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 5800 system is designed as one integrated instrument. The cobas® 6800/8800 systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 5800 or cobas® 6800/8800 systems software which assigns test results for all tests as either target not detected, EBV DNA detected < LLoQ (lower limit of quantitation), EBV DNA detected > ULoQ (upper limit of quantitation), or a value in the linear range LLoQ < x < ULoQ. Results can be reviewed directly on the system screen, exported, or printed as a report. Nucleic acid from patient samples and added lambda DNA-QS molecules is simultaneously extracted. In summary, viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the glass particles with elution buffer at elevated temperature. Selective amplification of target nucleic acid from the sample is achieved by the use of a dual target virus specific approach from highly-conserved regions of the EBV located in the EBV EBNA-1 gene and the EBV BMRF gene. Selective amplification of DNA-QS is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with the EBV genome. A thermostable DNA polymerase enzyme is used for amplification. The target and DNA-QS sequences are amplified simultaneously utilizing a universal PCR amplification profile with predefined temperature steps and number of cycles. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).10-12 Any contaminating amplicon from previous PCR runs is eliminated by the AmpErase enzyme, which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C. The cobas® EBV master mix contains two detection probes specific for EBV target sequences and one for the DNA-QS. The probes are labeled with target-specific fluorescent reporter dyes allowing simultaneous detection of EBV target and DNA-QS in two different target channels.13,14 The fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probe to the specific single-stranded DNA templates results in cleavage by the 5'-to-3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Real-time detection and discrimination of PCR products is accomplished by measuring the fluorescence of the released reporter dyes for the viral targets and DNA-QS. 10. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 2227421. 11. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459. 12. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: Structural basis for specificity and catalysis. Cell. 1995;80:869-78. PMID: 7697717. 13. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485. 14. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518. en

cobas® EBV Test

For accurate monitoring of Epstein-Barr virus (EBV) in transplant patients

IVD

Setting a new standard for transplant patients

The cobas® EBV test provides reliable, standardized, high-quality results for the improved management of transplant patients at risk of infection. The test is intended as an aid in the diagnosis and management of Epstein-Barr Virus (EBV) in transplant patients, with results used to guide treatment decisions.²The test is for use on the automated cobas® 5800/6800/8800 systems.

Product specification	Value
Sample type	EDTA plasma
Minimum amount of sample required	350 µL*
Sample processing volume	200 µL
Analytical sensitivity	18.8 IU/mL
Linear range	35.0 IU/mL to 1E+08 IU/mL
Genotypes detected	Genotypes 1 and 2
Overall precision	SD 0.02 - 0.17 log₁₀

User profile

Select your user profile

cobas® EBV Test

Setting a new standard for transplant patients

Epstein-Barr virus

Benefits at a glance²

Overview

Ordering information

Technical documents

cobas® EBV test for cobas® 5800/6800/8800 systems performance²

cobas® EBV test for cobas® 5800/6800/8800 systems performance²

Compatible products

Contact us

User profile

Select your user profile

cobas® EBV Test

Setting a new standard for transplant patients

Epstein-Barr virus

Benefits at a glance2

Related categories

Overview

Ordering information

Technical documents

cobas® EBV test for cobas® 5800/6800/8800 systems performance2

cobas® EBV test for cobas® 5800/6800/8800 systems performance2

Compatible products

Related Products

Contact us

Benefits at a glance²

cobas® EBV test for cobas® 5800/6800/8800 systems performance²

cobas® EBV test for cobas® 5800/6800/8800 systems performance²